These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 11718037)

  • 21. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
    Kam KM; Yip CW
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management and outcome of tuberculosis patients who fail treatment under routine programme conditions in Malawi.
    Harries AD; Nyirenda TE; Kemp JR; Squire BS; Godfrey-Faussett P; Salaniponi FM
    Int J Tuberc Lung Dis; 2003 Nov; 7(11):1040-4. PubMed ID: 14598962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis.
    Seung KJ; Gelmanova IE; Peremitin GG; Golubchikova VT; Pavlova VE; Sirotkina OB; Yanova GV; Strelis AK
    Clin Infect Dis; 2004 Nov; 39(9):1321-8. PubMed ID: 15494909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
    Prasad R; Verma SK; Sahai S; Kumar S; Jain A
    Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of anti-tuberculosis drug resistance on the treatment outcome of pulmonary tuberculosis patients receiving DOTS in Riyadh, Saudi Arabia.
    Singla R; Al-Sharif N; Al-Sayegh MO; Osman MM; Shaikh MA
    Int J Tuberc Lung Dis; 2002 Jul; 6(7):585-91. PubMed ID: 12102297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Resistance and efficacy of treatment in relapse pulmonary tuberculosis].
    Tu D; Zhang L; Su J
    Zhonghua Jie He He Hu Xi Za Zhi; 2000 Nov; 23(11):666-8. PubMed ID: 11225030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes.
    Yoshiyama T; Yanai H; Rhiengtong D; Palittapongarnpim P; Nampaisan O; Supawitkul S; Uthaivorawit W; Mori T
    Int J Tuberc Lung Dis; 2004 Jan; 8(1):31-8. PubMed ID: 14974743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
    Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
    Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is there an increased risk of TB relapse in patients treated with fixed-dose combination drugs in Indonesia?
    Suryanto AA; van den Broek J; Hatta M; de Soldenhoff R; van der Werf MJ
    Int J Tuberc Lung Dis; 2008 Feb; 12(2):174-9. PubMed ID: 18230250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
    Nolan CM; Goldberg SV
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of recurrence among MDR-tB cases 'successfully' treated with standardised short-course chemotherapy.
    Migliori GB; Espinal M; Danilova ID; Punga VV; Grzemska M; Raviglione MC
    Int J Tuberc Lung Dis; 2002 Oct; 6(10):858-64. PubMed ID: 12365571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin.
    Moulding TS; Le HQ; Rikleen D; Davidson P
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):743-8. PubMed ID: 15182145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of acquired drug resistance during short-course directly observed treatment of tuberculosis in an area with high levels of drug resistance.
    Cox HS; Niemann S; Ismailov G; Doshetov D; Orozco JD; Blok L; Rüsch-Gerdes S; Kebede Y
    Clin Infect Dis; 2007 Jun; 44(11):1421-7. PubMed ID: 17479936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Twice-weekly intermittent chemotherapy during the maintenance phase of the short-course treatment for new patients with pulmonary tuberculosis].
    Wada M; Mizoguchi K; Okumura M; Mitarai S; Hoshino H; Ohmori M; Uchimura K; Yoshiyama T; Ogata H
    Kekkaku; 2006 May; 81(5):363-9. PubMed ID: 16768170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A study on the clinical efficacy of a combination regimen with levofloxacin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis].
    Chen QL; Chen L; Yin JJ
    Zhonghua Jie He He Hu Xi Za Zhi; 2003 Aug; 26(8):454-7. PubMed ID: 14505519
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance.
    Shamaei M; Marjani M; Chitsaz E; Kazempour M; Esmaeili M; Farnia P; Tabarsi P; Amiri MV; Mirsaeidi M; Mansouri D; Masjedi MR; Velayati AA
    Int J Infect Dis; 2009 Sep; 13(5):e236-40. PubMed ID: 19285897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternative anti-tuberculosis regimen including ofloxacin for the treatment of patients with hepatic injury.
    Szklo A; Mello FC; Guerra RL; Dorman SE; Muzy-de-Souza GR; Conde MB
    Int J Tuberc Lung Dis; 2007 Jul; 11(7):775-80. PubMed ID: 17609053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-tuberculosis drug resistance in community and prison patients, Orel Oblast, Russian Federation.
    Spradling P; Nemtsova E; Aptekar T; Shulgina M; Rybka L; Wells C; Aquino G; Kluge H; Jakubowiak W; Binkin N; Kazeonny B
    Int J Tuberc Lung Dis; 2002 Sep; 6(9):757-62. PubMed ID: 12234130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Representative drug susceptibility patterns for guiding design of retreatment regimens for MDR-TB.
    Rich ML; Socci AR; Mitnick CD; Nardell EA; Becerra MC; Bonilla C; Bayona J; Seung KJ; Furin J; Farmer PE; Mukherjee JS
    Int J Tuberc Lung Dis; 2006 Mar; 10(3):290-6. PubMed ID: 16562709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Analysis of short-term effects of short-course intermittent chemotherapies of the World Bank Loaned Project].
    Wen S; Su Y; Zhang F
    Zhonghua Jie He He Hu Xi Za Zhi; 1996 Dec; 19(6):357-9. PubMed ID: 9596819
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.